The Indian government has recently implemented a policy prohibiting medical representatives (MRs) from meeting doctors directly in central government hospitals. This move aims to eliminate unethical relationships between pharmaceutical companies and healthcare professionals, ensuring that medical decisions remain unbiased and in the best interest of patients.
Under this policy, MRs are no longer allowed to enter hospital premises to promote their products. Instead, pharmaceutical companies are required to communicate information about new drug launches via email. This directive was issued by Dr. Atul Goel, Director General of Health Services, and applies to all central government hospitals, CGHS Wellness Centers, and polyclinics.
The government has also emphasized the importance of prescribing generic medicines only, as mandated by the National Medical Commission. Despite previous instructions, some doctors continued to prescribe branded medicines, prompting stricter enforcement measures. Institutions have been directed to ensure compliance, with non-compliant individuals facing potential disciplinary action.
This policy is part of the government’s broader efforts to curb the doctor-pharma nexus and promote ethical medical practices. While some medical representatives have expressed concerns about the impact on their profession, the government maintains that these measures are necessary to prioritize patient welfare
